Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cybin ( (TSE:CYBN) ) just unveiled an announcement.
Cybin Inc. has reported its fiscal year 2025 financial results and highlighted significant business developments. The company is advancing its Phase 3 CYB003 program for major depressive disorder and Phase 2 CYB004 program for generalized anxiety disorder, with strategic partnerships to enhance clinical and manufacturing capabilities. Collaborations with Osmind and Thermo Fisher Scientific aim to expedite development and commercialization, supported by a robust intellectual property portfolio.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin Inc. is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is engaged in creating novel therapies to address unmet needs in mental health care, with a particular focus on major depressive disorder and generalized anxiety disorder.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
Find detailed analytics on CYBN stock on TipRanks’ Stock Analysis page.